Relmada Therapeutics, Inc. (RLMD) stock analysis

Healthcare · Biotechnology

From the 10-K filed 2026-03-19

How it makes money

It currently generates no revenue and relies entirely on external capital to fund the development of its experimental drug candidates.

As a clinical-stage biotechnology company, it has not yet commercialized any products. Its financial model is defined by significant operating losses incurred while it navigates the multi-year process of clinical trials and regulatory approval.

Earnings potential depends entirely on the future successful development and regulatory clearance of its pipeline, specifically NDV-01 and sepranolone, which are intended to address unmet medical needs in oncology and neurology.

What protects it: the moat

It relies on securing and defending intellectual property and patent positions to maintain exclusivity for its clinical-stage drug candidates.

The company's competitive standing is protected by its efforts to patent its novel drug formulations and delivery technologies. However, management acknowledges that these positions remain highly uncertain and subject to complex legal challenges.

Without commercial products, its primary defense against competitors is the hope that its proprietary development programs will eventually receive regulatory approval, granting it exclusive market rights.

What growth costs

It must continuously reinvest significant capital into clinical trials, regulatory submissions, and third-party manufacturing to advance its pipeline toward potential commercialization.

Growth costs consist primarily of research and development expenses, including site-specific study costs, compensation for specialized personnel, and fees paid to third-party contract research organizations.

Maintaining the pipeline requires constant cash outflows for clinical study execution and compliance, while growth is fueled by acquiring or licensing new clinical-stage candidates, such as the recent additions of NDV-01 and sepranolone.

What could damage it

Failure to achieve primary efficacy endpoints in clinical trials leads to the immediate termination of programs, destroying the value of all prior capital investments.

The company's existence depends on the positive outcome of clinical trials. When a study is deemed futile or fails to meet statistically significant efficacy markers, it must abandon the program entirely, rendering the time and capital previously dedicated to that drug useless.

About Relmada Therapeutics, Inc.

Relmada Therapeutics, Inc. operates as a clinical-stage biotechnology company in the United States. The company focuses on the development of NDV-01, a controlled-release intravesical formulation of gemcitabine and docetaxel, which is in Phase 2 clinical trial for patients with aggressive forms of non-muscle invasive bladder cancer; and Sepranolone, a neurosteroid epimer of allopregnanolone, which is Phase 2b-ready for the potential treatment of prader-willi syndrome, tourette syndrome, excessive tremor, and other diseases related to excessive GABAergic activity. The company has an agreement with Asarina Pharma AB and Trigone. Relmada Therapeutics, Inc. was founded in 2004 and is headquartered in Coral Gables, Florida.

Other companies in Biotechnology